Skip to main content
BBIO
NASDAQ Life Sciences

BridgeBio Pharma Increases Equity Incentive Plan by 2 Million Shares; Director's Term Concludes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$69.63
Mkt Cap
$13.65B
52W Low
$41.8
52W High
$84.94
52W Position info
67% above low
Off High info
18% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BBIO sits 67% above its 52-week low of $41.8.

Summary

BridgeBio Pharma stockholders approved adding 2 million shares to its equity incentive plan, potentially diluting existing shares by over 1%, and a director's term concluded.


Key Events · Corporate Governance and Compliance · BBIO

  • Equity Incentive Plan Expanded

    Stockholders approved an amendment to the 2021 Stock Option and Incentive Plan, increasing the number of shares reserved for issuance by 2,000,000 shares.

  • Potential Dilution

    This authorization represents a potential dilution of approximately 1.02% of the company's outstanding shares, valued at around $139 million.

  • Director's Term Concludes

    Dr. Randal W. Scott resigned as a Class I director upon the completion of his term, effective June 22, 2026. His resignation was not due to any disagreement with the company.

  • Annual Meeting Results

    Stockholders also approved executive compensation on a non-binding advisory basis, opted for annual advisory votes on compensation, and ratified Deloitte & Touche LLP as the independent auditor for 2026.


Analysis · BBIO · Life Sciences

Stockholders approved an amendment to the company's equity incentive plan, authorizing an additional 2 million shares for future issuance. This represents a potential dilution of approximately 1.02% of current outstanding shares, valued at around $139 million based on the current stock price. While necessary for employee compensation and retention in a life sciences company, this authorization increases the potential for future dilution. Additionally, a director's term concluded, with the resignation not attributed to any disagreements, making it a routine board change.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $69.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $41.80 to $84.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $78.67 info
Change: +$7.98 (+11%) info
Market Cap: $15.325B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $78.67 info
Change: +$7.23 (+10%) info
Market Cap: $15.325B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $78.67 info
Change: +$8.00 (+11%) info
Market Cap: $15.325B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $78.67 info
Change: +$12.92 (+20%) info
Market Cap: $15.325B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $78.67 info
Change: +$13.32 (+20%) info
Market Cap: $15.325B info